Introduction
Multiple myeloma is characterized by the accumulation of malignant plasma cells in the bone marrow compartment. 1 These terminally differentiated B-lymphocytes all produce an identical immunoglobulin (Ig) known as a monoclonal protein, the laboratory hallmark of this malignancy. Although the predominant cell type in the bone marrow of these patients has the characteristics of a plasma cell, the low proliferative activity of these cells has raised the possibility that less mature B-lymphocytes represent the proliferating population, which give rise to the overabundant malignant plasma cell. Recent advances in molecular biological techniques have led to the determination of the stage of B cell differentiation at which this disease begins.
The tumor cells which reside within the bone marrow are supported by a nonmalignant population of stromal cells which produce cytokines that enhance myeloma cell growth and prevent apoptosis. Moreover, the tumor cells themselves orchestrate the production of cytokines by these nonmalignant bone marrow cells which can lead to a further increase in tumor cell burden. Recent demonstration of the Kaposi's sarcoma-associated herpesvirus in some of these nonmalignant cells provides an additional novel mechanism by which the bone marrow microenvironment may support this B cell malignancy.
The malignant cell of origin
The low proliferative rate of the phenotypically identified malignant cell 2 and inability of these cells to sustain tumor growth in vivo as demonstrated by kinetic studies 3 earlier precursor cells may be responsible for the proliferation of the malignant population. The presence of a circulating tumor component without obvious plasma cell morphology also suggests that less mature lymphocytes may be part of the clone as well, which could explain the dissemination of the disease throughout the bone marrow. 4 In addition, evidence for tumor cells at even earlier stages of hematopoietic differentiation came from studies showing the high rate of acute nonlymphoblastic leukemia in these patients and the presence of non-lymphoid surface markers on malignant plasma cells. 5, 6 A variety of molecular biological techniques have subsequently been used to characterize further the cell types which are part of the malignant clone in this B cell malignancy.
Immunogenotypes
Because of the monoclonal nature of the Ig synthesized by the malignant cells, the genes, which lead to the production of this protein, can be used as molecular markers capable of identifying surface markers on the malignant cells. In addition, specific characteristic changes in these genes occur at different stages of B cell differentiation; and thus allow determination of which cell types in this lineage are part of the tumor clone.
Each antibody-producing B cell produces a single type of antibody. Early in normal B cell development, rearrangement of four separate gene segments leads to the development of the heavy chain portion of a unique functional antibody. 7 These gene segments encode the constant region which determines the class of antibody (eg C for IgM, C␥ for IgG, C␣ for IgA), and three other gene segments which encode the variable region of the heavy chain; variable (V H ), diversity (D), and joining (J H ). [7] [8] [9] [10] Since these latter three joined segments encode for the specific antigen recognition site of the final antibody, the recombination of genes which comprise this region must be unique to each antibody-producing cell. Thus, specific changes in these genes occur during the maturation of the antibody-producing B cell. Most of a single functional heavy chain variable region is encoded by one of ෂ50 functional V H genes whereas shorter stretches of amino acids are derived from one or more D and one of six functional J H genes. [7] [8] [9] [10] In addition, increased antibody specificity is accomplished by the addition of non-germline nucleotides (N segments). 11 Once a functional heavy chain rearrangement has occurred, the (and, if unsuccessful, ) light chain undergoes a similar rearrangement of V L , J L , and C genes. 12 Additional specificity of the antibody is rendered by the mutation of nucleotides within the specific areas of the variable region which bind antigen directly known as complementarity determining regions (CDRs) leading to enhanced avidity of the antibody for antigen. 13 This process of somatic mutation occurs late in B cell development in germinal centers. Following the secretion of a functional active antibody, this process ceases within this terminally differentiated B cell.
In multiple myeloma, the properties of the Ig genes allow precise determination of the stage of B cell development during which malignant transformation occurred. Specifically, comparison of the myeloma V H gene sequence to the most homologous germline gene has shown marked somatic mutation (median 8%) of this gene segment. 14 This frequency of somatic mutation is only found in the most differentiated B cells after antigenic stimulation has occurred. In further support of an antigenically driven process leading to these malignant clones, analysis of regions which bind antigen within these genes, the CDRs, demonstrates a marked predilection for somatic mutations compared to the other parts of the gene which are primarily responsible for maintaining the structural integrity of the molecule, the so-called framework regions (FRs). 15 Moreover, in antigenically driven cells, mutations occurring within the CDRs should be more often associated with a change in the encoded amino acid compared to those changes occurring in the FRs. Indeed, the ratio of replacement to silent mutations is double in the CDRs compared to the FRs in multiple myeloma.
14 Importantly, analysis of multiple clones shows no clonal diversity in V H genes from myeloma patients, and determination of these sequences during the course of their disease shows no clonal evolution. 14, 16, 17 These results differ from other B cell tumors originating in germinal centers at earlier stages of B cell differentiation. 18 Analysis of CDR3 genes comprised of the D, J H and N segments further supports the high rate of somatic mutation with a high replacement to silent ratio. 19 These segments also show a lack of clonal diversity. 19 Thus, these results suggest that the final oncogenic event in myeloma occurs very late in B cell differentiation. Although some studies have suggested the existence of a pre-class switched (C-containing) monoclonal cell in this disease, [20] [21] [22] the frequency of these cells and their contribution to the malignant process has not been established. Using colony hybridization techniques, our laboratory has not been able to demonstrate C-containing clonal cells in myeloma. 23 
Use of specific V H , D, and J H genes
The approximately 50 functional V H genes have been divided into seven families based on sequence homology ranging in size from one (V H 6) to 22 (V H 3). 24, 25 In mature B cells, V H gene family use is generally proportional to the number of functional genes. 26 However, specific genes have been shown to be overused by immature B cells including V H 4.21. 27 This same gene has also been frequently expressed by the autoreactive and malignant B cells from patients with autoimmune disease and several B cell neoplasms, respectively. [28] [29] [30] In fact, diffuse large cell lymphomas, which develop from relatively immature B cells, use this V H gene in nearly two-thirds of cases. 30 In myeloma, although V H gene family usage closely parallels results found in normal B cells, V H 4.21 usage has only rarely been observed. 31 Since this gene encodes antibodies capable of recognizing self-antigens, the elimination of B cells expressing this gene prior to plasma cell development would prevent production of possibly deleterious auto-antibodies. Thus, this finding also supports that the final transforming event occurs at the stage of terminal B cell differentiation in myeloma. The CDR3 length in myeloma is comparable to normal B cells but fusion of multiple D genes is much more common than in normal B cells. 19 In myeloma CDR3s, N-region insertion is minimal compared to normal B cells. Since studies of normal plasma cells have not been completed, it is unknown whether this increased frequency of D-D fusion and lack of N-region addition is specific to myeloma. Use of specific J H and D genes is quite comparable to usage in mature B-lymphocytes further supporting the late B cell origin of myeloma.
Immunophenotype
Early studies using aneuploidy as a basis of malignant plasma cell determination suggested the existence of myeloid, megakaryocytic, and T cell markers on the surface of the malignant clone in myeloma. 4 However, the use of these so-called 'lineage-specific markers' was problematic since it was learned that normal plasma cells could express these same antigens. 32 The presence of a unique molecular marker, the Ig gene expressed by the malignant clone, has allowed a more precise determination of surface markers present on the malignant clone.
CD34
CD34 is expressed on early hematopoietic precursors including the pluripotent stem cell. 33 However, some B cells also express this surface marker. 34 Reinfusion of hematopoietic cells selected for CD34 can lead to rapid and sustained engraftment following myeloablative chemotherapy. 35 Since we and others had previously demonstrated the presence of tumor cells in not only the bone marrow but also the blood of myeloma patients, it became of both biological and clinical importance to determine whether any malignant cells expressed this stem cell marker in myeloma patients. Initially, CD34
+ cells were purified from myeloma patients' bone marrow using a combination of an immunoadsorption column and flow sorting. Using a sensitive PCR-based assay with primers derived from the unique CDRs expressed by the patient's malignant clone, no tumor cells were detected in the CD34-expressing population. 36 Several other groups have confirmed this initial report 37, 38 although two reports have suggested the existence of a CD34 + tumor cell in myeloma. 39, 40 However, CD34 selection with an immunoadsorption column (Ceprate; Cellpro, Bothell, WA, USA) on autologous peripheral stem cell autografts resulted in a reduction of autograft tumor burden by 2.7 to Ͼ4.5 logs as quantified using a PCR assay with patient-specific Ig gene primers. 41 Results of a recently completed randomized phase III trial using the Ceprate device 42 confirmed this marked reduction in autograft tumor burden (median, 3.3 logs) with the majority of autografts rendered 'tumor-free' to the sensitivity of the assay (1:700 000). Despite this manipulation, engraftment was not different between the patients receiving CD34-selected compared to -unselected autografts.
CD10
CD10, also known as the common acute lymphoblastic leukemia antigen (CALLA), was originally described as a surface antigen present on the cells of some human acute lymphoblastic leukemias. 44 Subsequently, it has been shown that CD10 is expressed on a wide variety of hematopoietic cells 45, 46 including B cells at early and late stages of differentiation. Studies of CD10 expression in myeloma have revealed that 123 CD10-expressing myelomatous plasma cells are present in only a minority (average 25%; range, 10-60%) of cases, and that myeloma cells expressing this antigen comprised only a small fraction of the malignant population. [47] [48] [49] [50] However, these earlier studies were based on relatively insensitive immunohistochemical studies. Using PCR with patientspecific V H gene primers, our group has found a small CD10-bearing malignant population in all cases studied. 51 This malignant CD10-expressing population in myeloma may play an important role in the pathogenesis of this disease. Since CD10 is expressed on germinal center B cells with a high proliferative activity, this malignant subpopulation in myeloma may represent the part of the clone which leads to growth and disease progression. In support of this, Wearne et al 52 have shown that the appearance of CD10-expressing tumor cells in the circulation occurs at the time of progression of myeloma.
CD19 and CD20
CD19 and CD20 are markers which become expressed during B cell development but are normally not present on terminally differentiated plasma cells. Although malignant bone marrow plasma cells also do not express these markers, 39 controversy exists regarding their presence on the circulating malignant population. 40, [53] [54] [55] Most studies have suggested that these markers are rarely found on the circulating malignant cells in myeloma patients. In fact, a recent study suggests not only that these circulating CD20-expressing cells are polyclonal but also that there is an inverse relationship between their numbers and prognosis in myeloma. 54 
CD38
Previous studies have demonstrated the high expression of CD38 on normal and malignant plasma cells. 56, 57 Although this antigen is not expressed on the pluripotent stem cell, it is expressed weakly on early lineage-committed cells.
58-60 If CD38 is expressed on all malignant cells, it may be possible to select for CD38-negative cells in autografts and render these products tumor-free. However, most studies of CD38 expression in myeloma have relied only on insensitive immunohistochemical techniques, which would be incapable of identifying an infrequent CD38-negative tumor cell in myeloma patients. Using flow sorting with anti-CD38 antibodies on peripheral blood mononuclear cells from myeloma patients, we identified a CD38-negative tumor cell population with a PCR-based assay in all myeloma patients. 61 However, the frequency of these circulating CD38 cells was markedly less than the CD38-expressing tumor cells in all cases. Thus, although tumor cells lacking CD38 exist in myeloma, they represent a relatively minor component of the malignant population. Since CD38 is not expressed on B cells prior to the plasma cell stage, however, these CD38-negative malignant cells may represent less mature malignant cells with a more proliferative capability.
The other cell of origin: the KSHV-infected dendritic cell

Stromal cells in myeloma
In myeloma, the role of the bone marrow microenvironment has been shown to be of increasing importance in supporting the malignant plasma cell. Specifically, nonmalignant stromal cells in the bone marrow from myeloma patients have been shown to promote the growth and prevent apoptosis of malignant plasma cells. [62] [63] [64] The cytokine IL-6 is produced in large quantities by these cells, and has been demonstrated to enhance growth and prevent apoptosis of the tumor cells. The production of this cytokine by stromal cells from myeloma patients has been shown to be enhanced by the adherence of malignant plasma cells. Thus, there is a close 'symbiotic' relationship between bone marrow stromal cells and tumor cells which results in an increase in tumor burden in myeloma patients. Many years ago, Hamburger and Salmon 65 suggested the existence of a specific factor only present in bone marrow macrophages from myeloma patients, which was required for supporting the malignant clone.
KSHV in other diseases
A new member of the herpes virus family was discovered in a case of Kaposi's sarcoma using representational difference analysis. 66 In addition to being frequently found in KS associated with or without HIV infection, 67 this virus, Kaposi's sarcoma-associated herpesvirus (KSHV) also known as herpesvirus 8, has been identified in two other B cell disorders, primary effusion lymphoma and multicentric Castleman's disease. 68, 69 Interestingly, this virus contains an IL-6 homologue 70 and all three of these diseases also share IL-6 as a growth factor. In these diseases, the virus has been localized to the malignant cells [71] [72] [73] although some controversy still exists in Kaposi's sarcoma. [74] [75] [76] Recently, KSHV has been found in cells bearing macrophage and dendritic cell markers cultured from the blood of Kaposi's sarcoma patients. 74 In one study, viral DNA has also been identified in peripheral blood B cells from nearly half of Kaposi's sarcoma patients. 75 Moreover, although latent virus was present in the Kaposi's sarcoma tumor itself, viral forms characteristic of KSHV replication have been localized within endothelial cells of KS lesions 72 and were present in the peripheral blood of these patients. 76 Thus although KSHV has been associated with the malignant population, some studies support infection of nonmalignant cells and suggest these cell types may disseminate the virus.
KSHV and multiple myeloma
Because of the IL-6-mediated support of malignant plasma cells by stromal cells derived from the bone marrow of myeloma patients, it was hypothesized that other growth factors for myeloma may result from KSHV infection of myeloma bone marrow macrophages. The virus, with its own unique growth factor(s), could be capable of supporting these nonmalignant cells. To this end, we examined the long-term marrow cultures established from the adherent cells of patients with myeloma. Using both a PCR assay with the viral specific primers derived from the KS330 233 fragment of ORF26 77 and in situ hybridization (ISH) with a KSHV-specific probe, we demonstrated KSHV in all patients with myeloma 78 except for one recently evaluated patient with early stage disease (Durie-Salmon stage IA). In addition, similar studies of patients with monoclonal gammopathy of undetermined significance (MGUS) have shown the presence of KSHV in a quarter of these individuals. MGUS patients also have a monoclonal Ig protein but do not have the clinical manifestations of myeloma although approximately one quarter will ultimately develop myeloma 124 or a related B cell malignancy within 25 years. 79 By contrast, normal subjects and patients with other hematological malignancies did not contain KSHV in their cultured cells.
Characterization of cells infected with virus using immunohistochemical techniques showed the presence of CD68, CD83, and fascin but lack of CD1a, CD31 and CD34. Thus, these results are consistent with a dendritic cell phenotype without characteristics of Langerhans cells 80 which is similar to the cell type found infected in cultures from the peripheral blood of Kaposi's sarcoma patients in one study. Recently, the human cytomegalovirus has been shown to be similarly derived from long-term cultures of PBMCs bearing macrophage and dendritic cell markers. 81 Thus, dendritic cells may serve as a reservoir for a wide variety of different viruses.
KSHV in fresh bone marrow and blood
Although the initial study showed the presence of KSHV in cells obtained by long-term culture, it was important to establish the presence of KSHV in fresh bone marrow and peripheral blood samples from myeloma and MGUS patients. Using in situ hybridization on serial sections, KSHV was found in bone marrow core biopsies of 18/21 myeloma patients 82 and one in six MGUS patients, but not in patients with other hematological malignancies or normal subjects. Immunohistochemical staining on serial sections suggested that the virus was present in dendritic cells which contained many long foot processes and comprised approximately 2% of the nucleated cells in these bone marrow biopsies. PCR confirmed the presence of KSHV in these bone marrow biopsies whereas normal subjects contained no detectable virus.
Studies of peripheral blood samples have rarely demonstrated KSHV in unenriched PBMCs (1/15) from myeloma patients whereas enrichment of these cells using immunomagnetic selection with CD68 and CD83 antibodies led to detection of KSHV in 33/40 myeloma patients and 5/20 MGUS patients. However, KSHV has not been identified in patients with other malignancies or Paget's disease of the bone, and only rarely (1/16) in normal volunteers. 83 Interestingly, in these studies, most myeloma patients lacking the presence of virus in blood and/or bone marrow were in remission following high-dose or conventional chemotherapy or were at an early clinical stage.
Preliminary studies have also suggested the presence of virus in several other disorders of terminal B cell differentiation including amyloidosis, Waldenstrom's macroglobulinemia, POEMS, and solitary plasmacytoma. 84 Regarding the latter B cell malignancy, KSHV has been found in the plasma cell tumor but not in uninvolved bone marrow. More cases are necessary to confirm this result which suggests the importance of the KSHV-infected dendritic cell in the development of disseminated multiple myeloma. Ongoing studies are also determining whether the presence of KSHV predicts which MGUS patients will ultimately develop myeloma. It is intriguing to note that approximately one quarter of patients with MGUS harbor virus, and a similar proportion transform to a B cell malignancy.
Determination of expression of KSHV-specific genes will help elucidate the state of the virus (latent vs lytic). Studies on cultured cells have shown the presence of viral IL-6, 78 suggesting the possible existence of some cells bearing lytic virus. However, the relevance of this data derived from long-term cultures to the situation in vivo is questionable. In Kaposi's sarcoma, although most cells are latently infected, a small proportion of cells bear lytic virus. 85 The expression of other viral proteins (MIPs) has been observed in preliminary studies from our group. Several recent reports have not found evidence of KSHV infection using serological assays. 86, 87 In addition, since Kaposi's sarcoma and myeloma have now both been linked to the same virus, it is puzzling that myeloma and Kaposi's sarcoma are not linked epidemiologically. 88 However, recent studies from our group demonstrate the presence of KSHV sequence variations from those frequently identified in Kaposi's sarcoma patients. Specifically, KSHV has been divided into three strain types (A, B and C) with most Kaposi's sarcoma patients showing A strain 89 whereas all of the myeloma patients show a B strain pattern. However, of even more significance, consistent mutational differences including deletions capable of causing frameshifts are found in KSHV from myeloma patients. In addition, other B cell disorders associated with KSHV also show a reduced frequency of A strain 90 consistent with our results in myeloma. Whether serological responses differ between KSHV strains is unknown. Of note, specific differences in KS330 233 sequences exist between our patients (3-8 bp), making PCR artifact an unlikely possibility. In five patients, sequencing of KSHV derived from the same patient's long-term cultures from bone marrow aspirate, fresh bone marrow biopsy, and dendritic cell-enriched peripheral blood shows identical sequences or a single base pair difference. Taken together, these data suggest that the virus in myeloma patients may be a variant of the one originally identified in Kaposi's sarcoma. 77 Another explanation for the lack of a serological response may be due to an immunological defect. Although immunodeficiency is one of the hallmarks of myeloma, the presence of serological responses to EBV in these patients makes a general humoral defect less likely. 86, 87 However, these patients may harbor a specific inability to respond to KSHV; and thus, are susceptible to its infection. In addition, viral infection of dendritic cells by other herpesviruses has been associated with functional defects of these cells.
Recently, measles virus infection of dendritic cells has been shown to disseminate the infections and induce apoptosis and reduce cytokine production by these cells leading to a poor immune response. [91] [92] [93] Similarly, KSHV infection of dendritic cells in myeloma may allow dissemination of the infection throughout the bone marrow and also contribute to the impaired immune response. In support of this, preliminary studies show a diminished expression of class II molecules and reduced ability of these KSHV-infected bone marrow dendritic cells from myeloma patients to stimulate allogeneic responder lymphocytes compared to similarly derived cells from normal subjects and patients with other B cell malignancies not infected with KSHV. 94 The malignant cell and the KSHV-infected dendritic cell: is there a relationship?
Since KSHV infection is known to occur in the general population; and, in fact, we have identified this virus in one normal volunteer's PBMCs, other factors must be required for the development of myeloma. Myeloma is frequently associated with translocations involving the immunoglobulin heavy chain gene locus, 95 and this has been recently demonstrated to involve DNA sequences responsible for heavy chain class switching. 96, 97 Recent cloning of non-immunoglobulin DNA near these breakpoints has identified new putative oncogenes. [97] [98] [99] Interestingly, preliminary analysis of one of these genes involved in a translocation involving 11q13 and 14q32 identifies a possible new member of the FGF family. Interestingly, also localized at 11q13 are two other FGF members including one, KS3, which was originally cloned from a Kaposi's sarcoma lesion and acts as a growth factor for this tumor. 100 Thus, it is possible that this new FGF member may provide the myeloma cells with the means of helping support the KSHV-infected dendritic cell. This would allow a cytokine loop to occur between the malignant cell and its virally infected nonmalignant partner.
Conclusions
These early studies suggest the importance of KSHV in the development of myeloma. However, much work is required to more firmly establish the role of this new herpesvirus in this B cell malignancy. Viral gene expression studies will help determine the viral state and provide information which may hint at possible therapeutic approaches. Studies both in vivo and in vitro demonstrating the effect of these virally infected cells on malignant plasma cells are critical. Infection of normal stroma with the virus from myeloma patients will allow a better understanding of the specific role of this virus in the pathogenesis of myeloma. Little is known about the effect of antiviral agents on KSHV in Kaposi's sarcoma in vivo and in vitro. 101, 102 Models allowing studies of virally infected samples from myeloma patients must be developed rapidly. This may lead to early clinical trials allowing a novel therapeutic approach to this incurable B cell malignancy.
